Leniolisib Trial Showed Promise for Immune Issues
In a small clinical trial, patients with primary immunodeficiencies saw reductions in organ size and improved lung function.
Updated on Oct. 14, 2026 in Asthma
Live Poll
Do you trust pharmaceutical companies to prioritize patient safety alongside the development of new treatments?
Pharming recently presented Phase II clinical trial data showing that oral leniolisib helped reduce spleen volume and lymph node lesions in 13 participants with primary immunodeficiencies. The 20-week study also tracked improvements in lung capacity for those living with these rare immune dysregulation conditions.
Why it matters
Managing immune dysregulation is complex, and these preliminary findings offer a potential path for addressing the physical symptoms associated with primary immunodeficiencies. Further study is needed to understand the long-term safety and efficacy of this treatment approach.
In a 20-week Phase II trial of 13 participants, those receiving twice-daily oral doses of leniolisib experienced a mean 26.4% reduction in spleen volume and an 8.0% increase in pulmonary diffusing capacity. One participant discontinued the study due to acute hepatitis.
The players
Pharming
A biotechnology company focused on the development of innovative protein replacement therapies and precision medicines for rare diseases.
The details
The trial used an intra-patient dose-escalation design, allowing participants to receive 10 mg, 30 mg, or 70 mg doses of leniolisib over the study period. Leniolisib works by targeting underlying immune dysregulation, which may help address systemic symptoms such as lymph node enlargement. Researchers observed a 33.7% mean reduction in the size of index lymph node lesions among four evaluable participants.
Timeline
October 14-17, 2026: Results were presented at the ESID meeting in Maastricht.
November 2026: Pharming expects to report results from a separate CVID trial.
Health Landscape
The development of targeted therapies like leniolisib represents an evolving shift toward precision medicine for primary immunodeficiencies. This research follows the pattern of findings typically shared at the ESID meeting to advance global knowledge in rare immune conditions.
If you are managing a primary immunodeficiency, it is worth discussing the potential role of emerging precision therapies with your specialist. Because this research is still in the trial phase, patients should continue to monitor their current symptom patterns and consult their physician regarding new treatment developments.
The takeaway
This trial highlights how precision medicine may eventually help manage systemic symptoms like organ enlargement in immune-deficient patients. Patients should track any changes in symptoms and discuss new clinical developments with their immunologist to stay informed about potential future care options.
What happens next
Pharming plans to report topline results from a separate Phase II trial in CVID in November 2026.
Further reading
Learn more about the latest innovations in Asthma and immune health.
Live Poll
Do you trust pharmaceutical companies to prioritize patient safety alongside the development of new treatments?
